纳米乳佐剂鼻内H5N1流感疫苗对雪貂的同源与异源致死攻击保护
该研究将植物源重组H5抗原与NE01纳米乳佐剂配制成鼻内疫苗,在雪貂中评估一剂或两剂免疫的免疫原性及对同源A/Indo和异源A/Vn致死攻击的保护。两剂免疫实现同源和异源攻击均100%存活且无体重下降,同源病毒清除更快(第3天 vs 第5天),提示鼻内NE01佐剂疫苗值得临床测试。
要点
- 两剂鼻内rH5/NE01疫苗对同源和异源H5N1致死攻击均达100%存活。
- 一剂免疫同源攻击存活88%,但未诱导血凝抑制抗体。
- 两剂免疫减少鼻洗液病毒排毒,同源清除快于异源。
核心结论
- 鼻内接种NE01佐剂配制的rH5疫苗可诱导系统及可能黏膜免疫,对同源或异源H5N1致死攻击提供保护。
- 该疫苗还增强病毒清除并减少排毒,强烈提示鼻内NE01佐剂流感疫苗值得临床测试。
研究设计与样本
- 研究在雪貂中评估植物源重组H5抗原与NE01佐剂配制的鼻内疫苗,比较一剂与两剂免疫方案。
- 检测免疫原性(IgG)、血凝抑制(HI)及同源(A/Indo)和异源(A/Vn)致死攻击保护。
主要发现
- 鼻内rH5/NE01一剂和两剂免疫后均诱导显著IgG水平,一剂未诱导HI,两剂后HI较低。
- 两剂免疫雪貂同源攻击后100%存活,体重丢失轻微,鼻洗液排毒较未免疫对照减少。
- 一剂免疫雪貂同源攻击后88%存活,伴中度体重丢失。
- 增加抗原剂量(45 µg rH5)评估交叉分支保护,两剂免疫后同源和异源攻击均100%存活且无体重丢失。
- 攻击后病毒清除同源(第3天)快于异源(第5天)。
临床怎么用
- 鼻内NE01佐剂rH5疫苗策略可能为流感防控提供黏膜免疫途径,但需临床测试验证。
- 两剂免疫方案在雪貂中显示对同源和异源H5N1攻击的完全保护,支持进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Flu vaccines administered intramuscularly (IM) have shown seasonally fluctuating efficacy, 20-60%, throughout the last 15 years. We formulated a recombinant H5 (rH5) in our Nanovax® (NE01) (rH5/NE01) adjuvant for intranasal vaccination in ferrets. We evaluated the regimen, one vs two immunization, and cross clade protection a ferret challenge model. METHODS: Plant derived recombinant H5 (rH5) antigen was formulated with NE01 and administered intranasally to ferrets. Immunogenicity (IgG), hemagglutination inhibition (HI), and protection against lethal challenge, were measured following one or two immunizations. Protection against homologous (strain A/Indo) and heterologous (strain A/Vn) was evaluated in ferrets following two immunizations. RESULTS: IN immunization with rH5/NE01 induced significant IgG levels after one and two immunizations. One vaccination did not induce any HI while low HI was measured after two immunizations. Homologous challenge with H5N1 A/ Indonesia showed 100% survival, with minimal weight loss in animals vaccinated twice compared to the unvaccinated controls. Analysis of nasal wash from these challenged ferrets vaccinated twice showed decreased viral shedding compared to unvaccinated controls. Interestingly, animals that received one vaccination showed 88% survival with moderate weight loss. Cross clade protection was evaluated using an increased antigen dose (45 µg rH5). Vaccinated animals demonstrated increased IgG and HAI antibody responses. Both homologous (A/Indo) and heterologous challenge (A/Vietnam) following two immunizations showed 100% survival with no loss of body weight. However viral clearance was more rapid against the homologous (day 3) compared to the heterologous (day 5) post challenge. CONCLUSION: Intranasal administration of NE01 adjuvant-formulated rH5 vaccine elicited systemic and probably mucosal immunity that conferred protection against lethal challenge with homologous or heterologous viral strains. It also enhanced viral clearance with decreased shedding. These outcomes strongly suggest that intranasal immunization using NE01 against flu infections warrants clinical testing.
引用
- Smith D, Streatfield SJ, Acosta H, et al. A nanoemulsion-adjuvanted intranasal H5N1 influenza vaccine protects ferrets against homologous and heterologous H5N1 lethal challenge. Vaccine. 2019. PMID: 31495593. doi:10.1016/j.vaccine.2019.08.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。